top of page
The Sound of Evolution
Ipragliflozin
Mechanism of action:
Ipragliflozin is a sodium-glucose cotransporter 2 inhibitor (SGLT2 inhibitor). Under normal conditions, the kidneys reabsorb nearly all filtered glucose. About 90% of this glucose is reabsorbed through SGLT2 in the epithelial cells of the proximal convoluted tubule, while the remaining 10% is reabsorbed by SGLT1. Ipragliflozin inhibits the function of SGLT2, preventing glucose reabsorption and causing most of the glucose to be excreted in the urine.
Reference(s):
Zhou Y et al. (2024). TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res.
bottom of page